CSD/BSE&NSE/PR/2026-2027
November 12, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences to Present Seven Scientific Posters Highlighting Its CNS Drug Discovery and Development Pipeline at Neuroscience 2026 (SfN), Washington DC, USA".**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Kandari Sangeetha Laxmi

Digitally signed by Kandari Sangeetha Laxmi
Date: 2026.11.12 11:34:01 +05'30'

K. Sangeetha Laxmi
Company Secretary

Encl.: as above

News Release

Suven Life Sciences to Present Seven Scientific Posters Highlighting Its CNS Drug Discovery and Development Pipeline at Neuroscience 2026 (SfN), Washington DC, USA.

Presentations showcase a diverse portfolio of clinical and preclinical drug candidates targeting neurodegenerative and neuropsychiatric disorders.

Hyderabad, India, 12-Nov-2026 - Suven Life Sciences, a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, announced that it will present seven scientific posters highlighting its drug discovery and development programs at Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), to be held in Washington, DC, USA, during 14–18, November 2026. Society for Neuroscience (SfN), is the world's largest organization of scientists and physicians devoted to understanding the brain and nervous system, famous for its massive annual global conference.

The presentations span a diverse range of therapeutic areas, including Alzheimer's Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder and Parkinson's Disease. The posters highlight Suven's continued progress in advancing innovative drug candidates through clinical and preclinical development.

Suven will present the following seven posters:

1. **SUVN-M8036:** A Multimodal Receptor Antagonist That Exhibits Antipsychotic and Anti-Aggressive-Like Effects in Animal Models. *N7; November 14, 2026, 1:00 PM-5:00 PM.*
2. **SUVN-I6107 (Tenaclidine):** Safety, Tolerability, and Pharmacokinetics of a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects. *JJ10; November 14, 2026, 1:00 PM-5:00 PM.*
3. **SUVN-L1101142:** A Novel Muscarinic M4 Positive Allosteric Modulator for the Treatment of Alzheimer's Disease and Schizophrenia. *JJ11; November 14, 2026, 1:00 PM-5:00 PM.*
4. **Samelisant:** Efficacy and Safety of an H3 Receptor Inverse Agonist for the Treatment of Narcolepsy With or Without Cataplexy: A Phase 3 Study. *EE18; November 16, 2026, 1:00 PM-5:00 PM.*
5. **SUVN-N9503012:** Efficacy of a Selective 5-HT1A Receptor Partial Agonist Intended for the Treatment of L-Dopa-Induced Dyskinesia. *W18; November 17, 2026, 8:00 AM - 12:00 PM.*
6. **Ropanicant (SUVN-911):** A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety in Patients with Major Depressive Disorder. *II27; November 17, 2026, 8:00 AM-12:00 PM.*
7. **Masupirdine (SUVN-502):** Baseline Characteristics from a Phase-3 Study in Alzheimer's Dementia with Agitation. *V22; November 17, 2026, 1:00 PM-5:00 PM.*

"Our participation at Neuroscience 2026 reflects the breadth and continued progress of Suven's CNS research and development pipeline. We have a diverse portfolio of drug candidates from several important therapeutic areas, including agitation, sleep disorders, depression, schizophrenia, Parkinson's disease and cognitive impairment. Our programs have advanced to the different stages of development, with candidates in Phase-3 and Phase-2 clinical development, alongside promising preclinical programs progressing towards clinical evaluation. We remain committed to advancing innovative therapies that have the potential to address significant unmet medical needs, improve outcomes for patients and create long-term value for the company" said Mr. Venkat Jasti, Chairman and Managing Director, Suven Life Sciences.

"The volume of scientific presentations at Neuroscience 2026 reflects our continued efforts in discovering and developing novel therapeutic approaches across multiple CNS targets. Our research encompasses different pharmacological mechanisms, including muscarinic M1 and M4 modulation, histamine H3 receptor inverse agonism, serotonin receptor modulation and nicotinic receptor antagonism. The presentations include findings from clinical studies of our advanced drug candidates as well as preclinical research supporting the development of our next-generation pipeline. We believe this integrated research and development approach will continue to strengthen our portfolio and support the advancement of differentiated CNS therapeutics" said Ramakrishna Nirogi, President and Chief Scientific Officer, Suven Life Sciences.

SfN attendees are invited to visit Suven's Exhibit Booth #423, where senior representatives from the company's scientific and business development teams of Suven Life Sciences, India & Suven Neurosciences, USA will be available throughout the conference to provide insights into Suven's clinical-stage neuroscience pipeline, ongoing development programs, future development strategy, and opportunities for collaboration and strategic partnerships.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus therapeutic areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing, enrollment completed); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; pivotal Phase-3 AWAKE study for EDS is initiated and Phase-2 study for Cataplexy is in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study completed and Phase-3 study is in planning); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), Tenaclidine (SUVN-I6107) for cognitive disorders (Phase-1 study is completed; Long term general toxicity and developmental toxicity studies in nonclinical models are in progress). In addition to these clinical assets, 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major world markets.

For more information, please visit our website http://www.suven.com.

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*